Should sunitinib still be used in the treatment of metstatic kidney cancer?
IMpower150: atezolizumab, chemotherapy and bevacizumab for NSCLC
Increasing overall survival in oligometastatic lung cancer patients
The importance of the Phase III JAVELIN LUNG 100 trial in non-small-cell lung cancer
Treatment landscape for HCC